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Summary
We studied the association of D-dimer with the risk of deep vein
thrombosis (DVT). D-dimer was measured in 474 patients more than
6 months after diagnosis of a first DVT and in 474 age- and sex-
matched controls. For D-dimer above the 70th percentile (130.5 ng/ml),
the odds ratio (ÖR) for DVT was 2.2 (95% CI, 1.6-2.9). The association
was unclianged with adjustnicn,! for olhcr risk fiiciors. Excluding parti-
cipants with Factor V Lcideri/prolhrombin 2021OA, or factors VIIIc or
IX above the 90th percentUe, the OR was 1.6 (95% CI, 1.1-2.3). The
risks of DVT with the joint prescncc of high D-dimer and either factor V
Leiaen or prothrombin 2021ΟΛ were increased 12.4-fold (95%
α 5,6-27.7) and 7.2-fold (95% CI 2.1-25.1), respectively. Higher D-
dimer concentration was associated with the risk of DVT, and was
supra-additive to the risks associated with factor V Leiden and the pro-
thrombin 20210A variant. Persistence of this association in the absence
of other hemostatic risk factors for DVT suggests that high D-dimer
may be related to other, äs yet unknown, risk factors for venous
thrombosis. Confirmation of these fmdings is desirable.
Introduction
Deep vein thrombosis (DVT) has an incidcncc of l to 3 per 1000 per
year. Factor V Leiden (1) and thc prothrombin 2021ΟΛ variant (2) arc
genctic risk factors for venous thrornbosis, and arc secn in 25'.·ί of
unselccted DVT patienls (3). Rccently, high levcls of coagulaiion fac-
tors VIII and IX have also been associated with venous ihrornbosis risk
(4>.5). A particular area of conirovcrsy is thc association of fibrinolytic
activity with risk of DVT (6-9).
-During fibrinolysis, fibrin fragment D-dimer is libcratcd upon
degradation of fibrin by thc major fibrinolytic cnzyme plasmin. Thus,
D-dimer concentration indicatcs both the reccnl produclion of and
degradation of fibrin. D-dimcr concenlralion increases wilh acuie DVT
(10) however, we are aware of only one sludy of Ihis marker in rclalion
lo venous thrombosis risk. This reccnl case-control sludy showed an
association betvvcen higher D-dimer and thrombosis in womcn aged
45-64 (9).
Others have studied the fibrinolysis markers plasminogen activator
inhibitor-1 and tissue plasminogen activator in relation to venous
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thrombosis. Most studies included patients during or a short time after
thrombosis, and were not conclusive (6, 8,11). The largest prospective
study to date of baseline fibrinolytic state in healthy subjects and risk of
future DVT failed to show a link between the two (7).
We measured concentrations of fibrin fragment D-dimer in a popu-
lation-based case-control study. We hypothesized that a higher concen-
tration' of D-dimer, äs an indicator of ongoing thrombin generation and
fibrinolysis, would be associated with an increased risk of DVT.
Methods
Study Design and Subjects
The Leiden Thrombophilia Study (LETS) is a population-based case-con-
trol study of risk factors for first DVT (12). There were 474 patients recruited
from three anticoagulation clmics in the Netherlands: Leiden, Amsterdam, and
Rotterdam. In the Netherlands, anticoagulation clinics monitor all patients on
coumann treatment for venous thrombosis. Inclusion cnteria were: (1) patients
living in the geographical area of the anticoagulation clinics, (2) age under 70,
(3) objective diagnosis of first DVT (positive compression ultrasound, impe-
dance plethysmography, or venogram), (4) DVT occurring between January l,
1988 and December 31, 1992, and (5) absence of mahgnancy. Evaluation for
inclusion in the study was performed using medical records from the hospital
and the anticoagulation clinics, and Information from primary physicians.
Patients received at least three months of anticoagulant therapy and were seen
at least six months after their DVT diagnosis. Ninety percent of eligible indivi-
duals participated. Control subjects were 474 healthy persons with no prior
history of venous thrombosis, the same sex and age within 5 years of the
patients, and no biological relationship to the patients. They were recruited by
asking each patient to find a control with the above characteristics, living in the
same geographic area. Patients' partners were also invited to participate in the
study. If a patient was unable to find a control, the first eligible person on the
list of patients' partners was chosen. Two hundred and twenty-five (47%) of the
controls were partners of other patients.
Participants provided informed consent allowing access to hospital records
and use of stored specimens for research. The Medical Ethics Committee of the
Leiden University Medical Center and the Institutional Review Board at the
University of Vermont approved this analysis.
All subjects completed a questionnaire regarding acquired risk factors for
venous thrombosis in a certain time period prior to the index DVT, or a similar
date for the controls. The acquired risk factors considered were: surgery or
hospitalizations in the year prior to the DVT, postpartum period within 30 days
of the DVT, pregnancy at the time of DVT, and hormone use at the time of
venipuncture and at the time of DVT.
Body mass index (BMI) was calculated (weight in kilograms/[height in
meters]2). Obesity was defmed äs a BMI a30 kg/m2. Elevated factors VIIIc and
IX antigen were defmed äs values above the 90th percentile of the control
populaüon distribution. Considering factor V Leiden and the prothrombin 20210A
allele, heterozygotes and homozygotes for each disorder were pooled for ana-
lysis.
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Table l Characteristics of the participants
Characteristic
Mean age in years (SD)*
Male Sex (%)*
ΒΜΙϊ30(%)
Coumarin use at phlebotomy
OCuseatDVTn


















t among controls, at the time the matched case had DVT
J women aged 16-45
DVT, deep vein thrombosis; BMI, body mass index; OC, oral contraceptive
Laboratory Methods
At the interview, blood was collected by venipuncture from the antecubital
vem into tubes contammg 106 mmol/L trisodium citrate. Plasma was prepared
by centnfugaüon at room temperature for 10 min at 2,000 X g and stored at
-70° C D-dimer was measured by enzyme-lmked immunosorbent assay
(ELISA) usmg two monoclonal antibodies against specific non-overlappmg
antigenic determinants (antibodies kindly provided by D. Collen and P.
Declerck). This assay detects fragment D-dimer of cross-lmked fibrin but not
fragments of fibrinogen or non-cross-lmked fibrin (10). The mterassay coeffi-
cient of Variation (CV) was 7.0%. The expected normal ränge (mean ± 2 SD),
established in 26 healthy volunteers is 6.8-189.9 ng/ml. As previously reported,
factor VIIIc was measured using a 1-stage clotting assay (4), and factor IX was










Among control subjects, associations between D-dimer and other characte-
ristics were analyzed using linear regression. Mean baseline D-dimer concen-
tration was compared between cases and controls using t-tests. The measure of
association between D-dimer and DVT was the odds ratio (OR)) äs determined
by uncondiüonal logistic regression, adjusting for the matching factors of age
and sex. Assessment of confounding was done using multivariate logistic
regression with D-dimer äs the main independent variable. Analyses were
repeated in subgroups defined by age, sex, oral contraceptive use, presence of
elevated factor VTIIc or IX levels, and presence of factor V Leiden or pro-
thrombin 20210A. To determine whether the association of D-dimer and DVT
could be exfl.ninrri hy thr rre«?n;v of othor hemo«liiiij ri-k liido^. w.s· rqwii
ted the anal) >:'·> .ιίΐί.'Γι'Μ.Ίΐιι1!!'!.· |·ιΊΐ;.·|·,ιΐιΐ·· .-.HM »·ΐιΙ:ι·! ί;κ·[θ! \ I oiiL'ii. pn·
thrombin 20Jli>.\. ι·ι οΚ··.:»!1,! ι.:.··.ο: \ III" οι ::k-!oi IX. W o imvMijMU'd ιΐκ.·
ι·η uMil
Fig. l Distribution of D-dimer m patients and controls. Each symbol repre-
sents the mean of five closest values. Honzontal lines represent median values
regression ar-;i Λ Ν."> !·.): i l i i l i v n i ΐ:ι>ι·.· ΐΓ.Μ'.,ιί.-
Results
Characteristics of patients and controls are shown in Table 1. The
mean age was 45 years (16-70 for patients, 16-73 for controls), 43% of
participants were men. Patients were more likely than controls to have
used oral contraceptives at the onset of DVT and were more likely to
be overweight. Among women aged 16-45,67% of patients were using
oral contraceptives at the time of DVT, compared to 39% of controls.
In the same age group among women, at the time of venipuncture 22%
of patients and 33% of controls were taking oral contraceptives. Twenty-
two percent of patients had a BMI >30 kg/m2, compared to 14% of the
controls. Only one control, compared to 48 patients (10%) was using
coumarin derivatives.
Among controls, D-dimer was positively associated with age, For
each 10-year increase in age, D-dimer was 19.8 ng/ml higher (95% CI,
11.0 to 28.6 ng/ml). Median D-dimer was 64.4 ng/ml in men, and
87.1 ng/ml in women (in controls). Arrjpng obese control subjects
median D-dimer was 99.2 ng/mL, compared to 71.8 ng/mL in non-
obese subjects. Among women aged 16-45, D-dimer was higher among
47 women using oral contraceptives; median 94.2 ng/ml compared to
72.8 ng/mL among non-users. When we take into account the bio-
chemical thrombophilic defects, factor V Leiden, prothrombin 20210A,
or elevated factors VIIIc or IX, median D-dimer was 104.7 ng/ml
among 106 subjects with any one of these defects compared to
70.4 ng/ml among 361 subjects without any defect.
Figure l illustrates that the distribution of D-dimer differed in
patients and controls, with higher values in patients. The median value
among patients was 102.4 ng/ml (ränge 9.1-1946.3 ng/ml) and among
controls it was 74.5 ng/ml (ränge 4.0-1608.9 ng/ml).
Table 2 shows the risk of DVT with each inereasing decile of D-
dimer, compared to the lowest decile. The relative risk of DVT was
increased for values above the 70th percentile of the distribution of
D-dimer. For values in the 8th, 9th and lOth deciles, relative to the first
decile, the crude odds ratios of DVT were 1.6 (95% CI 0.9-2.9), 1.8
(95% CI 1.0-3.2), and 3.2 (95% CI 1.8-5.6), respectively. The associa-
tion of D-dimer with DVT was not substantially altered with adjust-
ment for age, oral contraceptive or coumarin use, and obesity (Table 3).
With adjustment for these factors, the risk of DVT remained higher
than 2.0 for values above the 70th percentile, and higher than 3.0 for
values above the 90th percentile (compared to those with values below
the 70th and 90th percentiles, fcspectively). Adjustment for C-reactive
protein concentration also did not influence the odds ratios substantially
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Table 2 Odds ratio of DVT by decile of the total distn-
bution of D-dimer ' Decile of D-dimer
(ng/ml)
1 (4 0-34 8)
2 (34 8-48 6)



































0 9 (0 5-1 6)
1 3 (0 7-2 4)
08(04-1 5)
1 1(06-20)
1 2 (0 7-2 3)
1 1 (0 6-2 0)
1 6 (0 9-2 9)
1 8 (1 0-3 2)
3 2 (1 8-5 6)
OR, odds ratio, CI, confidence mterval
Töbk 3 Odds ratio of DVT % D-dimer greater than
ihe 70th or 90lli perccntiles of the total distnbuüon D-dimer* Number of Number of
Controls Paüents
< P 70 327
i P 70 140
<P90 421









2 8 (1 9-4 0)
OR (95% CI)i
1 0 (ref)
2 5 (1 8-3 5)
1 0 (ref)
3 3 (2 2-4 9)
* D-dimer 70th percentile = 130 5 ng/ml, 90th percentile = 223 6 ng/ml
t OR adjusted for matchmg variables (age and sex)
t OR additionally adjusted for obesity, and coumann or oral contraceptive use at the time
of DVT and at the üme of phlebotomy
P 70 = 70th percentile
P 90 = 90th percentile
rf
j t
(data not shown). Exclusion ot subjects using coumanns at the time of
phlebotomy did not aller these Undings. Risks werc shghtly Icss after
exclusion of subjects with hemostatic defects (factor V Leiden, pro-
thrombm 202IOA, and high Factor Vllfc 01 faclor IX)· OR l 6 (95%
CI 1.1-2.3) for D-dimer above the 70th percentile, and OR 1.9 (95%
CI 1.1-3.2) for D-dimer abo\e the 90th percentile.
There wcrc some extreme values for D-dimer. While these values
may be due toanalytical vanabihty of D-dimcr. to assess «hcihci \ery
high values of D-dimer mduenced Ihe Undings, we cxcludcd 5 patients
and 2 conlrols with D-dimer >1000 ng/ml trom ihe dnaKsis The odds
ralios icmaincd the same (data not show n)
The risk of DVT for D-dimer above the 70th percentile was shghtly
higher in women than men, with odds ratios of 2 3 (95% CI l 6-2 3)
among women and l 7 (95% CI l 1-2 7) among men For D-dimer
above the 9Qikßercentile these odds ratios were 2.4 (95% CI l 44 1)
and 3.0 (95% CI l 84 9), respectively. D-dimer over the 70fh percentile
in combination with either oral contraceptive use or age 5:30 mcreased
the risk of DVT 12.7-fold (95% CI 4.041), and 2 0-fold (95%
CI l 2-3 6) compared to groups with lower D-dimer and absence of
these charactenstics
The odds ratio of DVT in the jomt presence of higher D-dimer and
Factor V Leiden was 12.4 (95% CI 5 6-27.7) This value is larger than
would be expected from the additive effect of the two factors (Table 4)
A similar supra-additive jomt risk of D-dimer in combination with
prothrombm 20210A, but not elevated factor VIIIc or factor IX, was
observed (Table 4)
The mean time from DVT to vempuncture among patients was
l 8 ± 0 9 years (ränge 0 5-5 6 years) There was no association of üme
between DVT and phlebotomy with D-dimer concentration (r = 0 05)
We analyzed the association of D-dimer with DVT in categones of
time between DVT and phlebotomy The odds raüos for DVT with
higher D-dimer in six time categones (0 5-1 years, 1-2 years, 2-3 years,
3-4 years, 4-5 years, and more than 5 years) are shown in Fig 2, nsks
did not vary substantially by time
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D-dimer s 70* Hemostatic




+ + 12.4 (5.6-27 7)


























Table4 Odds ratio of DVT
for D-dimeTgreater than the













0.5-1 1-2 2-3 3-4
Time (years)
>4
Fig. 2 Odds ratio of DVT for D-dimer above the 70th percentile by time
between DVT and venipuncture. The time between DVT and venipuncture was
divided into yearly increments. The odds ratio of DVT for D-dimer above the
70th percentile was calculated for patients and controls enrolled during each
time interval
Discussion
The main finding of this study is an association of D-dimer with risk
of DVT, with a 2.5-fold increased risk for D-dimer above the 70th per-
centile, and 3-fold increased risk for D-dimer above the 90th percentile.
This association was not influenced by other risk factors such äs
obesity and oral contraceptive use, but risks were slightly lower with
adjustment for known hemostatic risk factors for DVT. The joint effects
of higher D-dimer and both the factor V Leiden and prothrombin
202 1 OA variant on the risk of DVT were supra-additive.
Resiihs hero suggesl a h\polhcsis that increased fibrin t'ormation and
fibrinolylic activitj. ,i.-.>.".-ed a» D dinier, is associated with vcnous
thrombosis, and can -i\\\ Iv dclivlcd wars after a DVT. Furthcr. the
persiMcnl associalion of D-dinicr wilh (he risk of DVT after adjuslmcnt
for kmnui biochemical and gcnctic risk factors. suggcsts the presence
of äs vcl undotcrmined risk faclors. of which D-dimer ma> be a marker.
Thereare twolines of. " .· · " ' ' . · ' · . . · ".·· !'·. , .·.'
genetic risk factors fo · « ' · · · · i . · · . . · ' . . i 1 : : . · ··
clear phenotype of heritable thrombophilia, approximately one-third do
not have a defmable hemostatic disorder (3). Second, in other family
studies known defects do not necessarily explain the tendency to
thrombosis (13).
Several fmdings here were compatible with other studies. These
include the cross-sectional finding of increasing D-dimer with older agc
(14,15). Also, äs in a recent study of women agcd 45-64 (9), we report
an increased risk of DVT with higher levels of D-dirner, and cxtendud
these results to men. Considering the generally negative fmdings of
studies that assessed the association of p^T with fibrinolytic factors,
such äs tissue plasminogen activator ."ntijron and plrKininopiMi iietivator
inhibitor-1 activity or antigen, our iiiiiliiu1·. Μίμαι·»! i l ia i ιΐκ· Mii'asiirx·
ment of D-dimer may reflect fibrin loini.ük'ii raili.'i ili.'in ilu· lihrinol>
tic state, per se.
Although factor V Leiden is a common risk factor for DVT, the
penetrance of thrombosis among heterozygotes is low, especially in the
absence of a positive family history of thrombosis (16,17). Our finding
of an enhanced risk of DVT with the cornbined presence of higher D-
dimer and factor V Leiden or prothronlbin 20210A suggests that D-
dimer might identif) indm.lnaK ν-ίΠι Ihi'v dofivl1· who aiv :ίι l i i i i l io i
riskof DVT. If coniniik' i l . i h i i l ' i i idi i i i ! nia> hau· dinical iiMr>k'aiioi)>
for evaluating the rok· o; KMIIIJ: Ιοί ΚΚΊΟΓ \' leiden. In Ι ! Η Ν I-IÜIIOM.
D-dimer may be a rn.üL'rlorihi ' inii-rai-lidii οΐ'οιίΐιτ. ii«. \vi i i n k i K m n
risk factors for DV1 \ui l i Ι.ΙΙΊΟΙ \ Ividi-norproi l iminhin 20.ΊΟΛ
A pointto discus^ i r > ι ΐ κ · inii 'i | ' ii ' iaiioii oi'oin Ιϊικϋιιμ<> i*· ih:ii hl(>od
was drawn after the ι<ΛΊΐ:Λ·ΐκν öl iliioinhiw-. and miühi ηοι ιορκ-ΌΝΐ
the levels prior to Ux i lüumluM·». l'hiMvIun· hi.ülicr I) diniiT ina> Iv ii
consequence rather 'iia:i a niarkor »>ί ι in· >::\\iv\\ paili<ip!i>M(>l(<i.'y o!'
DVT. It is possible il:.:; ν^ιοιι«. (i.niiauc i'iom l h.· DVT. ivMil l i i ip in
venous stasis, mighi .·.!;:·..· iiv.il i l i i o i n b i i N l i H i i i a l i o n and !>>!·>. <nid
result in a systemk ·ιι.ι!»>.:·>ι· πι D ιΙιιη»·ι Λ ΐ ι ΐ ι · ι · ι ι ΐ ι < ι ΐ ΐ ( < ι ι on a Tronic
basis. The study design and analysis minimized this potential bias, äs
supported by the lack of differences in the association of D-dimer with
DVT by time from DVT to prilebotomy. Also our finding is compatible
with other observations (9) including those of a prospective association
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between higher D-dimer and incidenße of myocardial infarction,
(18,19). Regardless, prospective confirmation of these fmdings is desi-
rable. A significant strength of the study is that it was based on all
admissions to three large anticoagulation clinics, so was generalizable
to a large population region.
In conclusion, we report that D-dirner appears to be a risk factor for
DVT. Independence of this association from known hemostatic risk
factors for DVT suggests that a high D-dimer concentration may be
related to other, äs yet unknown, risk factors for venous thrombosis.
A clinical role for D-dimer assessment among patients with thrombosis
requires further elucidation.
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